Implication of protein kinase R Gene quantification in hepatitis C Virus Genotype 4 induced Hepatocarcinogenesis

Diagnostic Pathology

Volumn 7, Issue 1, 2012, Pages

  Mohamed, Amal A ^a   Nada, Ola H ^b   El Desouky, Mohamed A ^c  

^a NATIONAL HEPATOLOGY AND TROPICAL MEDICINE RESEARCH INSTITUTE   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Genotype 4 HCV; Hepatocellular carcinoma; Liver; PKR

Indexed keywords

MESSENGER RNA; PROTEIN KINASE R;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; UPREGULATION; VIROLOGY; VIRUS LOAD;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; EIF-2 KINASE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; UP-REGULATION; VIRAL LOAD;

EID: 84864960323     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-7-103     Document Type: Article

References (41)

1. Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol 2005, 3:27-44. 10.1186/1477-7819-3-27, 1166580, 15907199.
2. De Mitri MS, Cassini R, Bagaglio S, Morsica G, Andreone P, Marino N, Bernardi M. Evolution of hepatitis C virus non-structural 5A gene in the progression of liver disease to hepatocellular carcinoma. Liver Int 2007, 27(Suppl 8):1126-1133.
3. Koike K. Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signalling pathways. J Gastroenterol Hepatol 2007, 22(Suppl 1):108-111.
4. Komurian-Pradel F, Rajoharison A, Berland JL, Khouri V, Perret M, Van Roosmalen M, Pol S, Negro F, Paranhos-Baccalà G. Antigenic relevance of F protein in chronic hepatitis C virus infection. Hepatology 2004, 40(Suppl 4):900-909.
5. Jiang CM, Diao ZY, Cui GX, Qian WH, Deng XZ, Xu K, Ding WL, Tan YF, Zhang Y. Expression and preliminary study of HCV F protein gene. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2007, 23(Suppl 2):134-137.
6. Fallahian F, Najafi A. Epidemiology of hepatitis C in the Middle East. Saudi J Kidney Dis Transpl 2011, 22(Suppl 1):1-9.
7. Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, Esteban R, Abdo AA, Harrison SA, Ibrahim N, Cacoub P, Eslam M, Lee SS. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011, 54(Suppl 6):1250-1262.
8. Afzal S, Idrees M, Akram M, Awan Z, Khubaib B, Aftab M, Fatima Z, Badar S, Hussain A. Mutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patients. Virol J 2010, 7:377-381. 10.1186/1743-422X-7-377, 3019161, 21194456.
9. Dong H, Cong WL, Zhu ZZ, Wang B, Xian ZH, Yu H. Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma. Zhonghua Zhong Liu Za Zhi 2008, 30(Suppl 9):702-705.
10. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35(Suppl 3)):421-430.
11. MacQuillan GC, de Boer WB, Platten MA, McCaul KA, Reed WD, Jeffrey GP, Allan JE. Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection. J Med Virol 2002, 68(Suppl 2):197-205.
12. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40(Suppl 3):667-676.
13. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998, 281:1309-1312.
14. Alisi A, Mele R, Spaziani A, Tavolaro S, Palescandolo E, Balsano C. Thr 446 phosphorylation of PKR by HCV core protein deregulates G2/M phase in HCC cells. J Cell Physiol 2005, 205(Suppl 1):25-31.
15. Deb A, Zamanian-Daryoush M, Xu Z, Kadereit S, Williams BR. Protein kinase PKR is required for platelet-derived growth factor signalling of c-fos gene expression via Erks and Stat3. EMBO J 2001, 20(Suppl 10):2487-2496. 125453, 11350938.
16. Shir A, Friedrich I, Levitzki A. Tumor specific activation of PKR as a non-toxic modality of cancer treatment. Semin Cancer Biol 2003, 13:309-314. 10.1016/S1044-579X(03)00045-2, 14563126.
17. Onuki R, Bando Y, Suyama E, Katayama T, Kawasaki H, Baba T, Tohyama M, Taira K. An RNA-dependent protein kinase is involved in tunicamycin induced apoptosis and Alzheimer's disease. EMBO J 2004, 23(Suppl 4):959-968. 380987, 14765129.
18. Terada T, Ueyama J, Ukita Y, Ohta T. Protein expression of double-stranded RNA-activated protein kinase (PKR) in intrahepatic bile ducts in normal adult livers, fetal livers, primary biliary cirrhosis, hepatolithiasis and intrahepatic cholangiocarcinoma. Liver 2000, 20(Suppl 6):450-457.
19. García MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C, Esteban M. Impact of protein kinase PKR in cell biology: from antiviral to ant proliferative action. Microbiol Mol Biol Rev 2006, 70(Suppl 4):1032-1060. 1698511, 17158706.
20. Gale M, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005, 436(7053):939-945. 10.1038/nature04078, 16107833.
21. Zhang P, Samuel CE. Protein kinase PKR plays a stimulus- and virus dependent role in apoptotic death and virus multiplication in human cells. J Virol 2007, 81:8192-8200. 10.1128/JVI.00426-07, 1951329, 17522227.
22. Short JAL. Viral evasion of interferon stimulated genes. Bioscience Horizons 2009, 2(Suppl 2):212-224.
23. Hung CH, Chen CH, Lee CM, Wu CM, Hu TH, Wang JH, Yen YH, Lu SN. Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma. J Viral Hepat 2008, 15(Suppl 1):58-65.
24. Toroney R, Nallagatla SR, Boyer JA, Cameron CE, Bevilacqua PC. Regulation of PKR by HCV IRES RNA: importance of domain II and NS5A. J Mol Biol 2010, 400(Suppl 3):393-412. 2902579, 20447405.
25. Kim CJ, Cho YG, Park JY. Human breast cancer cells contain elevated levels and activity of the protein kinase, PKR. Oncogene 2000, 19(Suppl 27):3086-3094.
26. Tamada Y, Nakao K, Nagayama Y. p48 Overexpression enhances interferon-mediated expression and activity of double-stranded RNA-dependent protein kinase in human hepatoma cells. J Hepatol 2002, 37(Suppl 4):493-499.
27. Nussbaum JM, Major M, Gunnery S. Transcriptional up regulation of interferon-induced protein kinase, PKR, in breast cancer. Cancer Lett 2003, 196(Suppl 2):207-216.
28. Hii SI, Hardy L, Crough T. Loss of PKR activity in chronic lymphocytic leukemia. Int J Cancer 2004, 109(Suppl 3):329-335.
29. Yan XB, Battaglia S, Boucreux D, Chen Z, Brechot C, Pavio N. Mapping of the interacting domains of hepatitis C virus core protein and the double-stranded RNA-activated protein kinase PKR. Virus Res 2007, 125(Suppl 1):79-87.
30. Esmat G, Metwally M, Zalata KR. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol 2007, 46(Suppl 4):620-627.
31. Saleem N, Mubarik A, Qureshi AH. Is there a correlation between degree of viremia and liver histology in chronic hepatitis C?. J Pak Med Assoc 2004, 54(Suppl 9):476-479.
32. Adinolfi LE, Utili R, Andreana A. Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci 2001, 46(Suppl 8):1677-1683.
33. Garaigorta U, Chisari FV. Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe 2009, 6(Suppl 6):513-522. 2905238, 20006840.
34. Chen GG, Lai PB, Ho RL, Chan PK, Xu H, Wong J, Lau WY. Reduction of double-stranded RNA-activated Protein Kinase in hepatocellular carcinoma associated with hepatitis B virus. J Med Virol 2004, 73:187-194. 10.1002/jmv.20074, 15122791.
35. Hiasa Y, Kamegaya Y, Nuriya H, Onji M, Kohara M, Schmidt EV, Chung RT. Protein kinase R is increased and is functional in hepatitis C virus-related hepatocellular carcinoma. Am J Gastroenterol 2003, 98(Suppl 11):2528-2534.
36. Shimada A, Shiota G, Miyata H, Kamahora T, Kawasaki H, Shiraki K, Hino S, Terada T. Aberrant expression of double-stranded RNA-dependent protein kinase in hepatocytes of chronic hepatitis and differentiated hepatocellular carcinoma. Cancer Res 1998, 58(Suppl 19):4434-4438.
37. Roh MS, Kwak JY, Kim SJ, Lee HW, Kwon HC, Hwang TH, Choi PJ, Hong YS. Expression of double-stranded RNA-activated protein kinase in small-size peripheral adenocarcinoma of the lung. Pathol Int 2005, 55(Suppl 11):688-693.
38. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ, Cobain TJ, Krusius T, Kolho E, Naukkarinen R. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994, 32(Suppl 4):884-892. 263157, 7913097.
39. Abdel-Hamid M, Edelman DC, Highsmith WE, Constantine NT. Optimization, assessment, and proposed use of a direct nested reverse transcription-polymerase chain reaction protocol for the detection of hepatitis C virus. J Hum Virol 1997, 1(Suppl 1):58-65.
40. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, Philips MJ, Portmann BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22(Suppl 6):696-699.
41. Roh V, Laemmle A, Von Holzen U. Dual induction of PKR with E2F-1 and IFN-alpha to enhance gene therapy against hepatocellular carcinoma. Cancer Gene Ther 2008, 15(Suppl 10):636-644.